Akero Therapeutics (AKRO) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKRO shares.
View AKRO analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued 12 month price objectives for Akero Therapeutics' stock. Their AKRO share price forecasts range from $58.00 to $83.00. On average, they anticipate the company's share price to reach $65.86 in the next year. This suggests a possible upside of 45.2% from the stock's current price.
View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts.

Akero Therapeutics' stock was trading at $54.80 on January 1st, 2023. Since then, AKRO stock has decreased by 17.2% and is now trading at $45.36.
View the best growth stocks for 2023 here.

Akero Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 6,330,000 shares, an increase of 8.0% from the August 15th total of 5,860,000 shares. Based on an average daily trading volume, of 678,200 shares, the short-interest ratio is presently 9.3 days.
View Akero Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our AKRO earnings forecast.

Akero Therapeutics, Inc. (NASDAQ:AKRO) released its earnings results on Friday, August, 11th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.01.

ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Invesco DWA SmallCap Momentum ETF (DWAS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS).

(AKRO) raised $75 million in an initial public offering on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."

Akero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.63%), State Street Corp (4.47%), Perceptive Advisors LLC (3.49%), General Atlantic L.P. (3.56%), Boxer Capital LLC (3.35%) and Commodore Capital LP (3.34%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White.
View institutional ownership trends.

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AKRO stock can currently be purchased for approximately $45.36.

Akero Therapeutics (NASDAQ:AKRO) has a market capitalization of $2.52 billion. The company earns $-112,030,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.akerotx.com. The company can be reached via phone at (650) 487-6488 or via email at akero@sternir.com.